Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
BJC Reports
|
November 8, 2024
Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial
Mark Beresford, Angela Casbard, Zoe Hudson, et al.
Journal of the American College of Cardiology
|
March 19, 2013
Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction
Julio A Panza, Thomas A Holly, Federico M Asch, et al.
The Lancet. Oncology
|
February 9, 2020
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Robert H Jones, Angela Casbard, Margherita Carucci, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
November 21, 2007
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial
Eric J Velazquez, Kerry L Lee, Christopher M O'Connor, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2026
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours
Robert H Jones, David J Pinato, Martin D Forster, et al.
The Lancet. Oncology
|
June 7, 2022
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Sacha J Howell, Angela Casbard, Margherita Carucci, et al.
Circulation. Heart Failure
|
March 22, 2013
Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease
Torsten Doenst, John G F Cleland, Jean L Rouleau, et al.
Heart (British Cardiac Society)
|
April 28, 2017
Regional left ventricular function does not predict survival in ischaemic cardiomyopathy after cardiac surgery
David L Prior, Susanna R Stevens, Thomas A Holly, et al.
Journal of the American College of Cardiology
|
August 9, 2014
Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]
Julio A Panza, Eric J Velazquez, Lilin She, et al.
Circulation
|
May 4, 2012
Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial
Marek A Deja, Paul A Grayburn, Benjamin Sun, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
BJC Reports
|
November 8, 2024
Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial
Mark Beresford, Angela Casbard, Zoe Hudson, et al.
Journal of the American College of Cardiology
|
March 19, 2013
Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction
Julio A Panza, Thomas A Holly, Federico M Asch, et al.
The Lancet. Oncology
|
February 9, 2020
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Robert H Jones, Angela Casbard, Margherita Carucci, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
November 21, 2007
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial
Eric J Velazquez, Kerry L Lee, Christopher M O'Connor, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2026
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours
Robert H Jones, David J Pinato, Martin D Forster, et al.
The Lancet. Oncology
|
June 7, 2022
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Sacha J Howell, Angela Casbard, Margherita Carucci, et al.
Circulation. Heart Failure
|
March 22, 2013
Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease
Torsten Doenst, John G F Cleland, Jean L Rouleau, et al.
Heart (British Cardiac Society)
|
April 28, 2017
Regional left ventricular function does not predict survival in ischaemic cardiomyopathy after cardiac surgery
David L Prior, Susanna R Stevens, Thomas A Holly, et al.
Journal of the American College of Cardiology
|
August 9, 2014
Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]
Julio A Panza, Eric J Velazquez, Lilin She, et al.
Circulation
|
May 4, 2012
Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial
Marek A Deja, Paul A Grayburn, Benjamin Sun, et al.
Page
of 9